Jazz Pharmaceuticals plc — Director's Dealing 2016

Jun 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-06-13

Reporting Person: Smith Karen L. (Global Head of R&D and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-13	Ordinary Shares	P	557.0	$149.6142	Acquired	12994	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $149.54 to $150.28. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were made.

F3: Includes 38 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2016.